The paradox of precision medicine

被引：42

作者：

Kimmelman, Jonathan ^{[1
,2
]}

Tannock, Ian ^{[3
]}

机构：

[1] McGill Univ, Biomed Eth Unit, Montreal, PQ, Canada

[2] McGill Univ, Dept Social Studies Med, Montreal, PQ, Canada

[3] Princess Margaret Canc Ctr, Div Med Oncol, Toronto, ON, Canada

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2018年 / 15卷 / 06期

关键词：

D O I：

10.1038/s41571-018-0016-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

According to the paradigm of precision medicine, the administration of agents targeting the molecular alteration detected in a particular patient's tumour reduces uncertainty in the clinical management of that patient. We describe how approaches to precision medicine can lead, paradoxically, to increased levels of uncertainty. We offer recommendations for how physicians can better navigate new uncertainties in precision medicine.

引用

页码：341 / 342

页数：2

共 9 条

[1] WHEN DO BASE RATES AFFECT PREDICTIONS [J].

BARHILLEL, M ;

FISCHHOFF, B .

JOURNAL OF PERSONALITY AND SOCIAL PSYCHOLOGY, 1981, 41 (04) :671-680

[2] Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study [J].

Camidge, D. Ross ;

Bang, Yung-Jue ;

Kwak, Eunice L. ;

Iafrate, A. John ;

Varella-Garcia, Marileila ;

Fox, Stephen B. ;

Riely, Gregory J. ;

Solomon, Benjamin ;

Ou, Sai-Hong I. ;

Kim, Dong-Wan ;

Salgia, Ravi ;

Fidias, Panagiotis ;

Engelman, Jeffrey A. ;

Gandhi, Leena ;

Jaenne, Pasi A. ;

Costa, Daniel B. ;

Shapiro, Geoffrey I. ;

LoRusso, Patricia ;

Ruffner, Katherine ;

Stephenson, Patricia ;

Tang, Yiyun ;

Wilner, Keith ;

Clark, Jeffrey W. ;

Shaw, Alice T. .

LANCET ONCOLOGY, 2012, 13 (10) :1011-1019

[3]

Fehrenbacher L, 2017, 2017 SAN ANT BREAST

[4] Personalized Medicine's Ragged Edge [J].

Fleck, Leonard M. .

HASTINGS CENTER REPORT, 2010, 40 (05) :16-18

[5] Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors The Individualized Cancer Therapy (iCat) Study [J].

Harris, Marian H. ;

DuBois, Steven G. ;

Bender, Julia L. Glade ;

Kim, AeRang ;

Crompton, Brian D. ;

Parker, Erin ;

Dumont, Ian P. ;

Hong, Andrew L. ;

Guo, Dongjing ;

Church, Alanna ;

Stegmaier, Kimberly ;

Roberts, CharlesW. M. ;

Shusterman, Suzanne ;

London, Wendy B. ;

MacConaill, Laura E. ;

Lindeman, Neal I. ;

Diller, Lisa ;

Rodriguez-Galindo, Carlos ;

Janeway, Katherine A. .

JAMA ONCOLOGY, 2016, 2 (05) :608-615

[6] Breaking a Vicious Cycle [J].

Hayes, Daniel F. ;

Allen, Jef ;

Compton, Carolyn ;

Gustavsen, Gary ;

Leonard, Debra G. B. ;

McCormack, Robert ;

Newcomer, Lee ;

Pothier, Kristin ;

Ransohof, David ;

Schilsky, Richard L. ;

Sigal, Ellen ;

Taube, Sheila E. ;

Tunis, Sean R. .

SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (196)

[7]

Kahneman D., 2011, Thinking, fast and slow

[8] The SHIVA01 trial: what have we learned? [J].

Le Tourneau, Christophe ;

Kamal, Maud ;

Bieche, Ivan .

PHARMACOGENOMICS, 2017, 18 (09) :831-834

[9] Level of Scientific Evidence Underlying Recommendations Arising From the National Comprehensive Cancer Network Clinical Practice Guidelines [J].

Poonacha, Thejaswi K. ;

Go, Ronald S. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (02) :186-191

← 1 →